Vanguard Asset Management
CRNX icon

Vanguard Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Vanguard Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
86,979
+6,453
+8% +$240K ﹤0.01% 1301
2026
Q1 		$2.92M Buy
+80,526
New +$3.6M ﹤0.01% 1258

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's CRNX Position: Q2 2026 in Review

Vanguard Asset Management increased its Crinetics Pharmaceuticals (CRNX) stake by 8% in Q2 2026, buying an estimated $240K and bringing the position to 86,979 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1301.

Vanguard Asset Management first reported a position in CRNX in Q1 2026 and has held it in 2 quarters since. 264 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Vanguard Asset Management held 86,979 shares of Crinetics Pharmaceuticals worth $3.25M as of Q2 2026.
  • Vanguard Asset Management bought 6,453 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $240K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1301 holding.
  • Vanguard Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 264 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.